MedTrace Logo

Second-line Treatment of Metastatic Colorectal Cancer

NCT06242067 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-02-05

No results posted yet for this study

Summary

The goal of this multicenter, single-arm, observational cohort study is to investigate the efficacy and safety of irinotecan in combination with trifluridine-tipiracil and bevacizumab in colorectal cancer with prior oxaliplatin and fluoropyrimidine-based chemotherapy (including 5-FU/capecitabine/S-1) exposure in the metastatic setting or within 12 months of recurrence.

Conditions

Interventions

DRUG

Trifluridine/tipiracil

patients received biweekly Trifluridine/tipiracil (30 mg/m2 twice daily; days 1-5), irinotecan (150 mg/m2; day 1) and bevacizumab (5 mg/kg; day 1).

Sponsors & Collaborators

  • The Affiliated Hospital of Qingdao University

    collaborator OTHER

  • Shandong Provincial Hospital

    collaborator OTHER_GOV

  • Qianfoshan Hospital

    collaborator OTHER

  • Binzhou People's Hospital

    collaborator OTHER

  • Binzhou Medical University

    collaborator OTHER

  • Yantai Yuhuangding Hospital

    collaborator OTHER

  • Linyi Tumour Hospital

    collaborator OTHER

  • Qilu Hospital of Shandong University

    lead OTHER

Principal Investigators

  • Jing Hao, Dr. · Qilu hospital of Shandong University, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-23
Primary Completion
2024-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06242067 on ClinicalTrials.gov